KAINOS LaboratoriesTSE:4556 39 PE Ratio without NRI is 17.52 as of Jul. 11, 2026, which is 107% above its 10-year median of 8.46. GuruFocus rates TSE:4556 with a GF Score™ of 39/100 and a GF Value™ of 円1,281.99 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 446 Medical Devices & Instruments companies, KAINOS Laboratories ranks better than 66.59% on this metric.
The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. As of today (2026-07-11), KAINOS Laboratories's share price is 円2268.00.
KAINOS Laboratories's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was 円129.43. Therefore, KAINOS Laboratories's PE Ratio without NRI for today is 17.52.
During the past 13 years, KAINOS Laboratories's highest PE Ratio without NRI was 17.52. The lowest was 6.68. And the median was 8.46.
KAINOS Laboratories's EPS (Basic) for the
six
months ended in Mar. 2026 was 円33.54.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was 円106.19.
KAINOS Laboratories (TSE:4556) PE Ratio without NRI Explanation
The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.
In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.
If a company loses money, the PE Ratio becomes meaningless.
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.
Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.
Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.
KAINOS Laboratories PE Ratio without NRI Related Terms
KAINOS Laboratories PE Ratio without NRI Historical Data
* Premium members only.
The historical data trend for KAINOS Laboratories's PE Ratio without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4556 vs ISRG, BDX, MDLN: PE Ratio without NRI Comparison
For the Medical Instruments & Supplies subindustry, KAINOS Laboratories's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
KAINOS Laboratories PE Ratio without NRI vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, KAINOS Laboratories's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where KAINOS Laboratories's PE Ratio without NRI falls into.
KAINOS Laboratories PE Ratio without NRI Calculation
The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. Regular PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than regular PE Ratio.
KAINOS Laboratories's Share Price of today is 円2268.00.
For company reported semi-annually, KAINOS Laboratories's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was 円129.43.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.
In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.
In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months.
For Forward PE Ratio, the earnings are the expected earnings for the next twelve months.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.
KAINOS Laboratories (TSE:4556) has a PE Ratio without NRI of 17.52 as of Jul. 11, 2026. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on KAINOS Laboratories and its competitors. This is 107% above median its historical median of 8.46. Over the past decade, KAINOS Laboratories' PE Ratio without NRI has ranged from 6.68 to 17.52. According to the industry distribution chart, KAINOS Laboratories ranks #149 out of 446 companies in the Medical Devices & Instruments industry, placing it in the top 33.4%.
Is KAINOS Laboratories' PE Ratio without NRI too high?
KAINOS Laboratories' current PE Ratio without NRI of 17.52 is 107% above median its 10-year median of 8.46. Over the past 10 years, this metric has ranged from a low of 6.68 to a high of 17.52. The Medical Devices & Instruments industry median PE Ratio without NRI is 23.47. KAINOS Laboratories' value of 17.52 is 25.4% below this industry median. Based on the distribution chart, KAINOS Laboratories ranks #149 out of 446 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, KAINOS Laboratories has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does KAINOS Laboratories' PE Ratio without NRI compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, KAINOS Laboratories ranks #149 out of 446 companies for PE Ratio without NRI. This puts KAINOS Laboratories in the upper half of its industry. The industry median PE Ratio without NRI is 23.47. KAINOS Laboratories' value of 17.52 is 25.4% below this benchmark. Historically, KAINOS Laboratories' own PE Ratio without NRI has ranged from 6.68 to 17.52 over the past decade. While the company's 10-year median is 8.46 vs. the industry median of 23.47, KAINOS Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio without NRI for a Medical Devices & Instruments company?
The median PE Ratio without NRI among Medical Devices & Instruments companies is 23.47, based on 446 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio without NRI significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. KAINOS Laboratories's current PE Ratio without NRI of 17.52 is 25.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio without NRI mean?
A high PE Ratio without NRI can signal that a stock is expensive relative to its fundamentals. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on KAINOS Laboratories and its competitors. For the Medical Devices & Instruments industry, the median PE Ratio without NRI is 23.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. KAINOS Laboratories's current PE Ratio without NRI is 17.52, which is 107% above median its own 10-year median of 8.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is KAINOS Laboratories stock overvalued right now?
Based on GuruFocus' analysis, KAINOS Laboratories (TSE:4556) is currently considered Significantly Overvalued. The stock's GF Value™ is 円1,281.99, compared to a current price of 円2,268.00 — trading 76.9% above its estimated fair value. The current PE Ratio without NRI is 17.52, which is 107% above median its 10-year median of 8.46 and 25.4% below the Medical Devices & Instruments industry median of 23.47. KAINOS Laboratories' overall GF Score™ is 39/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio without NRI calculated?
PE Ratio without NRI is calculated from a company's financial statements. For KAINOS Laboratories (TSE:4556), the current PE Ratio without NRI is 17.52 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is KAINOS Laboratories (TSE:4556) Overvalued in 2026?
Based on GuruFocus' analysis, KAINOS Laboratories stock appears to be overvalued.
The current stock price of 円2,268.00 is trading 76.9% above its estimated GF Value™ of 円1,281.99.
GuruFocus considers KAINOS Laboratories to be Significantly Overvalued.
Key valuation signals for TSE:4556:
PE Ratio without NRI: 17.52 (107% above median its 10-year median of 8.46)
GF Value™: 円1,281.99 vs. price of 円2,268.00 (76.9% above fair value)
Industry Position: 25.4% below the Medical Devices & Instruments median (#149 of 446)
No single metric tells the full story. See the TSE:4556 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
KAINOS Laboratories Inc is focused on the development, manufacture, marketing, distribution, and import/export of pharmaceuticals, diagnostic reagents, and related chemical products. It also manufactures, sells, and exports/imports physicochemical measuring equipment for medical use.
39GF Score
Get the complete analysis for TSE:4556
PE Ratio without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4556 has been successfully added to your 
